Essential medicines

Brhlikova P, Persaud N, Osorio-de-Castro CGS, Pollock AM. Essential medicines lists are for high income countries tooBMJ 2023;382:e076783. download

Brhlikova P, Deivanayagam TA, Babar Z-U-D, Osorio-de-Castro CGS, Caetano R, Pollock AM. Essential medicines concept and health technology assessment approaches to prioritising medicines: selection versus incorporation. Journal of Pharmaceutical Policy and Practice 2023;16:88. download

Green A, Lyus R, Ocan M, Pollock AM. Registration of essential medicines in Kenya, Tanzania and Uganda: a retrospective analysisJ R Soc Med 2023:01410768231181263. download

Baldeh A-O, Millard C, Pollock AM, Brhlikova P. Bridging the gap? Local production of medicines on the national essential medicine lists of Kenya, Tanzania and UgandaJournal of Pharmaceutical Policy and Practice 2023;16:18. download

Sevcikova P, Pollock AM. India jeopardizing ‘pharmacy of the world’ status. Asia Times. 15 November 2022.

Pollock AM, Sevcikova P. Unregulated ‘innovation’: India’s medicine problem. The Conversation. 14 November 2022.

Mehta A, Brhlikova P, McGettigan P, Pollock AM, Roderick P, Farooqui, HH. Systemic antibiotic sales and WHO recommendations, India. Bulletin of the World Health Organization Online First: 22 August 2022. download

Pollock AM, Ocan M, Sevcikova P. East African countries should prioritise their essential medicines for drug registration. The Conversation 18 Nov 2020.

Lyus R, Pollock AM, Ocan M, Brhlikova P. Registration of antimicrobials, Kenya, Uganda and United Republic of Tanzania, 2018. Bulletin of the WHO 2020;98(8):530–538. download

Brhlikova P, Maigetter K, Murison J, Agaba AG, Tusiimire J, Pollock AM. Registration and local production of essential medicines in Uganda. Journal of Pharmaceutical Policy and Practice 2020;13(1):31. download

McGettigan P, Roderick P, Kadam A, Pollock AM. Threats to global antimicrobial resistance control; centrally approved and unapproved antibiotic formulations sold in India. British Journal of Clinical Pharmacology. 2018. download

Millard C, Kadam A, Mahajan R, Pollock AM, Brhlikova P. Availability of brands of six essential medicines in 124 pharmacies in Maharashtra. Journal of Global Health. 2018;8(1). download

McGettigan P, Pollock AM. India not doing enough to stop sale of unapproved antibiotics. Asia Times. 14 October 2017.

Pollock AM, McGettigan P. Indian government not doing enough to tackle sale of unapproved antibiotics. The Conversation. 11 Oct 2017.

McGettigan P, Roderick P, Kadam A, Pollock AM. Access, Watch, and Reserve antibiotics in India: challenges for WHO stewardship. The Lancet Global Health. 2017;5(11):e1075–6. download

Ofori-Asenso R, Pollock AM, Brhlikova P. Poor prescription practices across Africa are putting patients at risk. The Conversation. 29 Aug 2016.

Ofori-Asenso R, Brhlikova P, Pollock AM. Prescribing indicators at primary health care centers within the WHO African region: a systematic analysis (1995–2015). BMC Public Health. 2016;16:724. download

Leng H, Pollock AM, Sanders D. The impact of the Medicines Control Council backlog and fast-track review system on access to innovative and new generic and biosimilar medicines of public health importance in South Africa. South African Medical Journal. 2016 Mar 17;106(4):350. download

Brhlikova P, Harper I, Subedi M, Bhattarai S, Rawal N, Pollock AM. Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal. Globalization and Health. 11(25). download

Millard C, Brhlikova P, Pollock AM. Social networks and health policy: the case of misoprostol and the WHO model essential medicine list. Social Science & Medicine. 2015;132:190–6. download

McGettigan P, Roderick P, Mahajan R, Kadam A, Pollock, AM. Use of fixed dose combination (FDC) drugs in India: central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or psychotropic drugs. PLoS Med. 2015;12(5):e1001826. download

Millard C, Brhlikova P, Pollock AM. Social networks and health policy: the case of misoprostol and the WHO model essential medicine list. Social Science & Medicine. 2015;132:190–6. download

Leng H, Sanders D, Pollock AM. Pro-generics policies and the backlog in medicines registration in South Africa: implications for access to essential and affordable medicines. GaBi Journal. 2015;4(2).

Atukunda, EC, Brhlikova P, Agaba AG, Pollock AM. Civil society organizations and medicines policy change: a case study of registration, procurement, distribution and use of misoprostol in Uganda. Social Science & Medicine. 2015;130:242–9. download

Evans V, Pollock AM. The proliferation of irrational metformin fixed-dose combinations in India. The Lancet Diabetes and Endocrinology. 2015;3(2):98–100. download

Birabwa C, Murison J, Evans V, Obua C, Agaba A, Waako P, et al. The availability of six tracer medicines in private medicine outlets in Uganda. Journal of Pharmaceutical Policy and Practice. 2014;7(18). download

Millard C, Pollock AM, Brhlikova P. Evidence versus influence in the WHO procedure for approving essential medicines: misoprostol for maternal health. BMJ. 2014;349:g4823. download

Atukunda EC, Brhlikova P, Agaba AG, Pollock AM. Registration, procurement, distribution, and use of misoprostol in Uganda: an interview-based observational study. The Lancet. 2013;382(Supplement 1):10. download

Chu CS, Brhlikova P, Pollock AM. Rethinking WHO guidance: review of evidence for misoprostol use in the prevention of postpartum haemorrhage. JRSM. 2012;105:336–47. download

Letter to WHO Expert Committee on the Selection and Use of Essential Medicines: Medicine Access and Rational Use

Application for deletion of misoprostol for PPH prevention